Literature DB >> 32974462

High-grade atrioventricular block occurring during percutaneous closure of patent foramen ovale: a case report.

Marion Kibler1, Halim Marzak1, Laurence Jesel1,2, Patrick Ohlmann1.   

Abstract

BACKGROUND: Percutaneous closure of patent foramen ovale (PFO) is recommended for patients presenting with PFO-related stroke. Acute high-grade conduction disturbances occurring during PFO closure procedure have not been previously reported. CASE
SUMMARY: We describe for the first time a case of reversible complete atrioventricular block which occurred during closure of a PFO. DISCUSSION: We hypothesized that the block was the result of atrioventricular node compression-likely caused by the right-atrial disc of the 35-mm PFO closure device. We suggest implanting smaller devices in order to prevent atrioventricular conduction disturbances.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Atrioventricular node; Case report; Cryptogenic stroke; High-grade atrioventricular block; Patent foramen ovale; Percutaneous closure

Year:  2020        PMID: 32974462      PMCID: PMC7501918          DOI: 10.1093/ehjcr/ytaa141

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


During patent foramen ovale closure, the device may rarely compress atrioventricular node and cause high-grade atrioventricular block. Correction can be achieved by prompt removal of the device, which should be replaced by a smaller one. Interventional cardiologists should be aware of this rare complication.

Introduction

Percutaneous closure of patent foramen ovale (PFO) is currently recommended for patients presenting with PFO-related stroke., The potential occurrence of conduction disturbances following PFO closure remains poorly investigated. To our knowledge, the onset of complete atrioventricular block (AVB) during PFO closure has not been previously reported in patients without a known history of conduction disturbances. 35-mm Amplatzer PFO Occluder®. Complete atrioventricular block (AVB), ventricular escape rhythm at 35 b.p.m. alternating with a second-degree AVB Normal AV nodal, intra-Hisian, and infra-Hisian conduction. Location of the device in the proximity of the AV node.

Case presentation

A 33-year-old woman was hospitalized for closure of a PFO. In the preceding weeks, she presented with a right hemiparesis deemed secondary to a stroke for which no clear cause was identified (cryptogenic stroke). Her past medical history was unremarkable, and the only routine medication taken by the patient on admission was aspirin 75 mg/day. Patent foramen oval was diagnosed on transthoracic echocardiography. A pre-procedural electrocardiogram did not reveal any atrioventricular or ventricular conduction disturbances (sinus rhythm; heart rate, 69 b.p.m.; PR, 150 ms; QRS, 82 ms; normal QRS axis; Supplementary material online, ). The patient underwent 24-h electrocardiogram monitoring during hospitalization for stroke in the neurovascular unit to identify the potential presence of conduction disorders or atrial fibrillation. Upon induction of general anaesthesia, PFO closure was performed under transoesophageal echocardiography (TEE) guidance and 10 F right femoral venous access. Transoesophageal echocardiography examination confirmed the presence of a PFO characterized by a large shunt (>30 bubbles). Owing to the large tunnel size (16 mm × 4.5 mm) and the presence of an atrial septal aneurysm (size: 10 mm), a 35-mm Amplatzer PFO Occluder® device (Abbott Vascular, Abbott Park, IL, USA; left- and right-atrial disc diameters: 25 and 35 mm, respectively) was selected to repair the defect (). Pre-procedural transoesophageal echocardiography images showing: (A) large right to left shunt (>30 bubbles); (B) length of patent foramen ovale tunnel (16 mm). Green arrow, large shunt; LA, left atrium; RA, right atrium. When the PFO was crossed, the left disc was successfully positioned without complications. However, positioning of the right disc was followed by the onset of a complete AVB. A ventricular escape rhythm at 35 b.p.m. alternating with a second-degree AVB was evident both on the anaesthetist’s monitoring screen and the TEE monitoring screen (). Although administration of atropine (0.5 + 0.5 mg) restored atrioventricular conduction within a few seconds, persistent complete AVB relapsed rapidly. We hypothesized that AVB stemmed from a compression of the atrioventricular node elicited by the right disc, which was therefore recaptured. Atrioventricular conduction was normalized as expected and transient cardiac pacing was performed through a left femoral venous access. We therefore opted for a smaller Amplatzer PFO Occluder® (left and right atrial disc diameters: 30 mm both). The device was successfully positioned and sealing of PFO at the end of the procedure was confirmed by the absence bubbles crossing the septum (through injection of agitated saline with Valsalva manoeuver). High-grade conduction disturbances did not recur both upon completion of the procedure and in the subsequent 48-h monitoring in the cardiac intensive care unit. The patient did not undergo steroid therapy because no recurrence of atrioventricular conduction disturbances was observed. The post-procedural electrocardiogram did not reveal any atrioventricular or ventricular conduction disturbances (sinus rhythm; heart rate, 86 b.p.m.; PR, 154 ms; QRS, 93 ms; normal QRS axis; Supplementary material online, ). Upon completion of the procedure, a dual antiplatelet therapy (aspirin and clopidogrel) was started and maintained 3 months. Per-procedural three-dimensional transoesophageal echocardiography showing the positioning of the 35-mm Amplatzer patent foramen ovale Occluder® device—which was accompanied by the onset of second-degree atrioventricular block on electrocardiogram. Green arrow, large shunt; LA, left atrium; RA, right atrium. On post-procedural Day 2, we performed an invasive electrophysiological study aimed at assessing the presence of pre-existent atrioventricular conduction disturbances. Recordings of His bundle electrogram were obtained with a diagnostic quadripolar electrode. The study revealed a normal atrioventricular nodal conduction with an AH interval of 80 ms (normal range: 55 − 125 ms). Intra-Hisian and infra-Hisian conduction were both normal, being characterized by a thin Hisian potential and a HV interval of 38 ms (normal range: 35 − 55 ms), respectively (). The device was located as close as 5 mm to the His bundle (). Moreover, the two proximal electrodes of the catheter were in contact with the umbrella ()—ultimately producing signal artefacts (). Artefacts were due to the contact of the two proximal electrodes with the right atrial disc during the cardiac cycle. These findings confirmed the close proximity between the device and the atrioventricular node, leading to the hypothesis that the implantation of the 35-mm Amplatzer PFO Occluder® device could have exerted a strong compression of the atrioventricular node and triggered AVB. Invasive electrophysiological study showing a normal atrioventricular nodal conduction with an AH interval of 80 ms. Intra-Hisian and infra-Hisian conduction was normal. The proximal electrodes of the catheter were in contact with the umbrella—ultimately producing a signal artefact (yellow arrow). X-ray performed during the invasive electrophysiological study. (A) Right anterior oblique view showing the proximity of the catheter and the right atrial disc of the Amplatzer patent foramen ovale Occluder® device. Note the proximity of the device to the His bundle (yellow line). (B) The red arrow indicates the contact between the proximal electrodes of the catheter and the patent foramen ovale Occluder® device (left anterior oblique view). Post-procedural transthoracic echocardiography confirmed the close proximity of the device to the septal tricuspid valve annulus (). After an unremarkable hospital stay, the patient was discharged on post-procedural Day 5. After a 6-month follow-up, there were no symptomatic recurrences. The electrocardiogram did not reveal any atrioventricular or ventricular conduction disturbances (sinus rhythm; heart rate, 75 b.p.m.; PR, 142 ms; QRS, 91 ms; normal QRS axis). Post-procedural transthoracic echocardiography showing the 30-mm device in place. Note the close proximity of the device to the septal tricuspid valve annulus. (A) Apical four chambers view. (B) Parasternal short-axis view. Ao, aorta; green arrow, large shunt; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

Discussion

We report a case of complete AVB occurring during the positioning of a 35-mm Amplatzer PFO Occluder® device. Notably, the replacement of the original apparatus with one of smaller size led to a complete regression of the conduction disturbances. We specifically hypothesized that the conduction disorder was caused by the right-atrial disc of the PFO Occluder® device—which was positioned in close proximity of the atrioventricular node. This in turn led to a compression injury of the adjacent atrioventricular conduction system. To our knowledge, only a few cases of high-grade AVB during percutaneous atrial septal defect (ASD) closure have been reported, mainly in patients with a known history of conduction disorders. Johnson et al. compared pre- and post-procedural electrocardiograms of patients who underwent percutaneous closure of ASD or PFO. Two patients developed a clinically significant post-procedural heart block. The first patient had a history of complex congenital cardiomyopathy repair, whereas the second had a pre-procedural second-degree AVB. El-Said et al. described a few cases of high-grade AVB occurring after percutaneous closure of ASD—which generally showed a spontaneous regression. The complete AVB observed in our patient was most likely caused by a direct compression injury to the atrioventricular node originating from the Amplatzer PFO Occluder® device. Because the typical path of atrioventricular conduction follows the anterior margin of the fossa ovalis,,, we should be aware that these areas might be injured or compressed during PFO closure. A previous report suggested that steroids may promote the recovery from atrioventricular conduction disturbances by decreasing oedema leading to AVB, but solid evidence is still lacking. Although there has been a report of acute AVB after percutaneous ASD closure, our patient—who notably had a negative history of previous atrioventricular conduction disorders—was the first to develop an acute high-grade AVB following a PFO closure. A large case series demonstrated that the most common electrophysiological disturbances following PFO closure were atrial fibrillation and delayed AVB—both of them being associated with female sex and a septal disc size larger than 30 mm.

Conclusion

We report for the first time a case of complete reversible AVB occurring during percutaneous PFO closure. The block was probably caused by direct compression of the atrioventricular node by the PFO Occluder® device. Interventional cardiologists should be aware that high-grade AVB may be a rare complication of PFO closure procedure. Correction can be achieved by prompt removal of the device, which should be replaced by one of smaller size.

Lead author biography

Marion Kibler is an interventional cardiologist at the University Hospital of Strasbourg (France). She is working also in the cardiac intensive care unit.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: none declared. Click here for additional data file.
TimeEvents
April 2018Cryptogenic stroke.
April 2018Transthoracic echocardiography: patent foramen oval (PFO) with a large shunt (>30 bubbles).
Transoesophageal echocardiography confirmed the diagnosis of PFO.
31 October 2018, time 0PFO percutaneous closure

35-mm Amplatzer PFO Occluder®.

31 October 2018, +15 minPositioning of the right disc of the device:

Complete atrioventricular block (AVB), ventricular escape rhythm at 35 b.p.m. alternating with a second-degree AVB

31 October 2018, +20 minThe right and left discs of Amplatzer PFO Occluder® were consecutively collected in a sheath: normalization of AV conduction.
31 October 2018, +25 minDecision to implant a smaller Amplatzer PFO Occluder® 30 mm:
Good positioning, no recurrence of AVB.
31 October 2018, +45 minTransfer to the cardiac intensive care unit.
2 November 2018Electrophysiological study

Normal AV nodal, intra-Hisian, and infra-Hisian conduction.

Location of the device in the proximity of the AV node.

5 November 2018Discharged from hospital.
March 2019Follow-up: asymptomatic patient.
  8 in total

1.  Device therapy for atrial septal defects in a multicenter cohort: acute outcomes and adverse events.

Authors:  Howaida El-Said; Sanjeet Hegde; Susan Foerster; William Hellenbrand; Jacqueline Kreutzer; Sara M Trucco; Ralf Holzer; Grant Burch; Ajay Mirani; Ramzi Nicolas; Diego Porras; Lisa Bergersen; John Moore
Journal:  Catheter Cardiovasc Interv       Date:  2014-10-13       Impact factor: 2.692

2.  Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.

Authors:  Jonathan N Johnson; Michelle L Marquardt; Michael J Ackerman; Samuel J Asirvatham; Guy S Reeder; Allison K Cabalka; Frank Cetta; Donald J Hagler
Journal:  Catheter Cardiovasc Interv       Date:  2011-05-11       Impact factor: 2.692

3.  Clinically apparent long-term electric disturbances in the acute and very long-term of patent foramen ovale device-based closure.

Authors:  Gianluca Rigatelli; Marco Zuin; Luigi Pedon; Roberto Zecchel; Fabio Dell'Avvocata; Antonio Carrozza; Marco Zennaro; Gianni Pastore; Francesco Zanon
Journal:  Cardiovasc Revasc Med       Date:  2016-10-29

Review 4.  Anatomy of the human atrioventricular junctions revisited.

Authors:  R H Anderson; S Y Ho; A E Becker
Journal:  Anat Rec       Date:  2000-09-01

5.  Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.

Authors:  Lars Søndergaard; Scott E Kasner; John F Rhodes; Grethe Andersen; Helle K Iversen; Jens E Nielsen-Kudsk; Magnus Settergren; Christina Sjöstrand; Risto O Roine; David Hildick-Smith; J David Spence; Lars Thomassen
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

6.  Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.

Authors:  Jean-Louis Mas; Geneviève Derumeaux; Benoît Guillon; Evelyne Massardier; Hassan Hosseini; Laura Mechtouff; Caroline Arquizan; Yannick Béjot; Fabrice Vuillier; Olivier Detante; Céline Guidoux; Sandrine Canaple; Claudia Vaduva; Nelly Dequatre-Ponchelle; Igor Sibon; Pierre Garnier; Anna Ferrier; Serge Timsit; Emmanuelle Robinet-Borgomano; Denis Sablot; Jean-Christophe Lacour; Mathieu Zuber; Pascal Favrole; Jean-François Pinel; Marion Apoil; Peggy Reiner; Catherine Lefebvre; Patrice Guérin; Christophe Piot; Roland Rossi; Jean-Luc Dubois-Randé; Jean-Christophe Eicher; Nicolas Meneveau; Jean-René Lusson; Bernard Bertrand; Jean-Marc Schleich; François Godart; Jean-Benoit Thambo; Laurent Leborgne; Patrik Michel; Luc Pierard; Guillaume Turc; Martine Barthelet; Anaïs Charles-Nelson; Christian Weimar; Thierry Moulin; Jean-Michel Juliard; Gilles Chatellier
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

7.  Reversible atrioventricular block associated with closure of atrial septal defects using the Amplatzer device.

Authors:  Kenji Suda; Marie-Josée Raboisson; Eric Piette; Nagib S Dahdah; Joaquim Miró
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

8.  Anatomy of the patent foramen ovale for the interventionalist.

Authors:  Jeff A McKenzie; William D Edwards; Donald J Hagler
Journal:  Catheter Cardiovasc Interv       Date:  2009-05-01       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.